FDA approves Nexium for treatment of teens

The FDA this week cleared AstraZeneca to market its heartburn treatment Nexium to children ages 12 through 17 for the treatment of gastroesophageal reflux disease. Nexium had global sales of $4.6 billion in 2005, making it the fifth best-selling drug in the world. The drug was approved for use in adults in February 2001.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions